-+ 0.00%
-+ 0.00%
-+ 0.00%

Aligos licenses pevifoscorvir sodium to Amoytop for Greater China in $25 million deal

PUBT·04/16/2026 10:01:10
Listen to the news
Aligos licenses pevifoscorvir sodium to Amoytop for Greater China in $25 million deal
  • Aligos Therapeutics signed exclusive license deal with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium for chronic hepatitis B in Greater China.
  • Agreement includes USD 25 million upfront payment.
  • Aligos eligible for up to USD 420 million in clinical, regulatory, sales milestones.
  • Deal includes tiered, high single-digit royalties on net sales in licensed territories.
  • Aligos retains rights outside Greater China, including U.S. and Europe.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604160600PRIMZONEFULLFEED9690955) on April 16, 2026, and is solely responsible for the information contained therein.